dabrafenib + trametinib

ApprovedRecruiting

0 views this week 0 watching⚡ Active🧬Featured in Oncology Pipeline Watch

Interest: 50/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Melanoma

Conditions

Melanoma, Non Small Cell Lung Cancer, Solid Tumor, Rare Cancers, High Grade Glioma

Trial Timeline

Dec 28, 2017 → Dec 28, 2030

NCT ID

NCT03340506

About dabrafenib + trametinib

dabrafenib + trametinib is a approved stage product being developed by Novartis for Melanoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT03340506. Target conditions include Melanoma, Non Small Cell Lung Cancer, Solid Tumor.

What happened to similar drugs?

3 of 20 similar drugs in Melanoma were approved

Approved (3) Terminated (2) Active (15)

✅ZelborafRocheApproved

✅Nivolumab + RelatlimabBristol Myers SquibbApproved

✅Fibrin Sealant (Tisseel) used in the Experimental Arm.BaxterApproved

❌Tasisulam-sodium + PaclitaxelEli LillyPhase 3

🔄Pembrolizumab + Lenvatinib + Placebo for lenvatinibEisaiPhase 3

🔄Ipilimumab + NivolumabOno PharmaceuticalPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (17)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07440290	Phase 2/3	Recruiting	Feb 1, 2026	Oct 1, 2029	Haematological Malignancy
NCT04961619	Pre-clinical	Completed	Dec 1, 2021	Dec 5, 2024	Melanoma
NCT04547946	Pre-clinical	Completed	Oct 15, 2021	Jun 7, 2022	Malignant Melanoma
NCT05171374	Pre-clinical	UNKNOWN	Sep 30, 2021	Sep 30, 2024	Melanoma Stage III
NCT04666272	Pre-clinical	Active	Dec 31, 2020	Feb 4, 2028	Melanoma
NCT04452877	Phase 2	Completed	Aug 19, 2020	Nov 7, 2024	Carcinoma, Non-Small-Cell Lung
NCT03975829	Approved	Active	Nov 4, 2019	Nov 6, 2026	Diffuse Astrocytoma
NCT02672358	Phase 2	Withdrawn	Sep 3, 2018	Dec 7, 2020	Non-Small-Cell Lung Cancer
NCT03551626	Phase 3	Completed	Aug 29, 2018	Sep 16, 2021	Malignant Melanoma
NCT02974803	Phase 2	Terminated	Feb 9, 2018	Jul 29, 2020	Melanoma
NCT03340506	Approved	Recruiting	Dec 28, 2017	Dec 28, 2030	Melanoma
NCT02367859	Phase 2	Completed	Jul 17, 2017	Jun 26, 2019	Ameloblastoma
NCT03091257	Phase 1	Active	Jun 21, 2017	Sep 15, 2026	Multiple Myeloma
NCT02083354	Phase 2	Completed	Mar 18, 2014	Apr 19, 2021	Cancer
NCT02034110	Phase 2	Completed	Mar 12, 2014	Dec 10, 2021	Cancer
NCT02039947	Phase 2	Completed	Feb 21, 2014	Feb 14, 2018	Melanoma and Brain Metastases
NCT01336634	Phase 2	Completed	Aug 5, 2011	Jan 7, 2021	Cancer

Competing Products

20 competing products in Melanoma

See all competitors

Product	Company	Stage	Hype Score
Binimetinib Oral Tablet	Biotrial	Phase 1	15
Tasisulam-sodium + Paclitaxel	Eli Lilly	Phase 3	32
[203Pb]VMT01 + [212Pb]VMT01 + Nivolumab	Perspective Therapeutics	Phase 1/2	33
[203Pb]VMT01 + [68Ga]VMT02	Perspective Therapeutics	Phase 1	23
FYB206 + Keytruda	Formycon AG	Phase 1	23
PLX3397	Daiichi Sankyo	Pre-clinical	26
PLX3397 + Pembrolizumab	Daiichi Sankyo	Phase 1/2	24
Trastuzumab deruxtecan	Daiichi Sankyo	Phase 2	39
DS-8273a + Nivolumab	Daiichi Sankyo	Phase 1	29
PLX3397 + vemurafenib	Daiichi Sankyo	Phase 1	21
enfortumab vedotin + pembrolizumab	Astellas Pharma	Phase 2	42
CP-461	Astellas Pharma	Phase 2	27
YM155	Astellas Pharma	Phase 2	35
YM155 + Docetaxel	Astellas Pharma	Phase 2	35
Denileukin diftitox	Eisai	Phase 2	35
E7080	Eisai	Phase 1	29
lenvatinib + pembrolizumab	Eisai	Phase 2	35
MORAb-004 (monoclonal antibody)	Eisai	Phase 2	35
Pembrolizumab + Lenvatinib	Eisai	Phase 2	39
Lenvatinib + Lenvatinib + Dacarbazine	Eisai	Phase 1/2	32